Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PORTIA-21 vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Prevention of pregnancy,Hormonal contraceptive (off-label: menstrual regulation, acne, hirsutism)
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.
400 mg orally once daily with food.
Terminal elimination half-life: 24-30 hours; clinical context: steady-state reached after 5-7 days, allows once-daily dosing
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Ethinyl estradiol undergoes first-pass metabolism in liver and gut via CYP3A4; levonorgestrel metabolized via CYP3A4 and reduction/sulfation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal (50-60% unchanged), fecal (30-40% as metabolites), minor biliary
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
98-99% bound, primarily to albumin and sex hormone-binding globulin (SHBG)
98% bound to albumin
2.8-4.1 L/kg, indicating extensive tissue distribution and accumulation in fat and reproductive organs
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 60-80% (first-pass metabolism reduces systemic availability); IV: 100%
Oral: 85-90%; IM: 95-100%
No dose adjustment required for mild to moderate renal impairment. Insufficient data for severe renal impairment (e GFR <30 m L/min/1.73 m²); use with caution.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For Child-Pugh class A, use with caution; no specific dose adjustment recommended.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily for 21 days, then 7 days placebo).
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for postmenopausal women. No specific geriatric dosing recommendations; follow standard dosing if prescribed off-label, but consider increased risk of thromboembolism and cardiovascular events.
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events from combination hormonal contraceptives. Risk increases with age (especially >35) and number of cigarettes smoked. Women >35 who smoke should not use this product.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders,Elevated blood pressure,Hepatic neoplasia or active liver disease,Gallbladder disease,Carbohydrate/lipid effects,Ocular changes (retinal thrombosis),Headache/migraine,Menstrual irregularities
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Carcinoma of endometrium or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No specific food interactions are known. Grapefruit juice may increase estrogen levels but not clinically significant; no dietary restrictions required. Take with food or milk if nausea occurs.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
Pregnancy category X. Contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular, skeletal, and neural tube defects due to progestin and estrogen exposure. Second and third trimesters: Increased risk of fetal genital abnormalities, urogenital malformations, and potential long-term effects on reproductive development. Use only if pregnancy is ruled out.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excreted in human milk. M/P ratio not established. May reduce milk production and composition. Potential for adverse effects in the nursing infant including jaundice, breast enlargement, and hormonal disruption. Use is contraindicated during breastfeeding.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
No safe dose in pregnancy. Contraindicated and should be discontinued immediately if pregnancy occurs. No dose adjustment possible due to teratogenicity.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Portia-21 (oral contraceptive pill containing levonorgestrel and ethinyl estradiol) requires strict adherence to a daily schedule; missed pills increase ovulation risk. First dose should be taken on the first day of menstruation for immediate contraceptive effect. Counsel patients that breakthrough bleeding is common in initial cycles but usually resolves. Concomitant use with CYP3A4 inducers (e.g., rifampin, St. John's wort) reduces efficacy and requires alternative contraception. Monitor blood pressure and consider increased thrombotic risk in smokers over age 35.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take one pill at the same time every day, even if you do not have sex that day.,If you miss a pill, refer to the package insert instructions; use backup contraception for 7 days if late by more than 12 hours.,Breakthrough spotting or nausea may occur initially but often improves; do not stop taking the pill.,Tell your doctor about all medications, including over-the-counter drugs and herbal supplements.,Smoking while taking this pill increases risk of blood clots, especially if over 35 years old.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PORTIA-21 vs ADQUEY, answered by our medical review team.
PORTIA-21 is a Oral Contraceptive that works by Oral contraceptive: inhibition of ovulation by suppressing gonadotropin release; increases viscosity of cervical mucus, reducing sperm penetration; alters endometrial receptivity.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PORTIA-21 and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PORTIA-21 is: One tablet (norgestimate 0.180 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PORTIA-21 and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PORTIA-21 is classified as Category C. Pregnancy category X. Contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular, skeletal, and neural tube defects due to progestin and est. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.